FTC wants more information on Novo’s $16.5B deal to boost Wegovy production

Becker's Healthcare May 6, 2024
Erica Carbajal

In February, Novo Nordisk agreed to buy Catalent for $16.5 billion. The Federal Trade Commission has since requested more information from the companies as it reviews the deal, The Wall Street Journal reported May 3.

This marks the agency’s second request for additional information regarding the deal, according to Catalent’s May 3 filing with the Securities and Exchange Commission. The move embodies the FTC’s heightened scrutiny on large mergers in recent years, especially in healthcare.

As part of...

Today's Sponsors

Today's Sponsor